VCP Antibody

What is VCP and why is it important in cellular biology?

VCP (valosin-containing protein) is a member of the ATPase associated with different cellular activities (AAA) family. It exists primarily as a hexamer and catalyzes ATP hydrolysis, though this activity differs from classical transport ATPases. VCP plays critical roles in multiple cellular processes including cell cycle regulation, protein degradation, organelle biogenesis, and vesicle-mediated protein transport. It is predominantly localized in the transitional elements between rough and smooth endoplasmic reticulum (ER), but can translocate to the nucleus upon stimulation with epidermal growth factor (EGF) . This versatility makes VCP a crucial protein for maintaining cellular homeostasis and function. The N-terminal region of VCP also binds to the DNA damage repair protein BRCA1, suggesting additional roles in nuclear function important for cell growth and survival .

What are the main types of VCP antibodies available for research?

VCP antibodies are available in both monoclonal and polyclonal formats, each with specific advantages for different research applications. Monoclonal antibodies, such as the mouse monoclonal antibody (60316-1-Ig), offer high specificity with defined epitope recognition and consistent lot-to-lot reproducibility . Polyclonal antibodies like the rabbit-derived antibody (#2648) recognize multiple epitopes on the VCP protein, potentially providing stronger signals in certain applications . These antibodies typically react with VCP from human and mouse samples, with some also recognizing rat and monkey VCP . The selection between monoclonal and polyclonal antibodies should be guided by the specific research needs, including the required sensitivity, specificity, and intended application.

How do I properly store and handle VCP antibodies to maintain their activity?

For optimal activity retention, VCP antibodies should be stored according to manufacturer recommendations. Most commercial VCP antibodies require storage at -20°C in appropriate buffers that maintain protein stability. For example, monoclonal antibodies are often stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Some purified antibodies remain stable for approximately one year after shipment when properly stored . The BD Transduction Laboratories purified mouse anti-VCP should be stored undiluted at -20°C .

For daily handling: avoid repeated freeze-thaw cycles by preparing small working aliquots; maintain sterile conditions when handling antibody solutions; and always centrifuge briefly before opening vials to collect all liquid at the bottom. While some manufacturers indicate that aliquoting is unnecessary for -20°C storage , dividing into smaller volumes is generally considered best practice for antibodies that will be accessed frequently.

What are the validated applications for VCP antibodies and their optimal working dilutions?

VCP antibodies have been validated for multiple applications with specific optimal dilution ranges:

For optimal results, researchers should titrate the antibody concentration for their specific experimental system . Antigen retrieval methods may significantly impact IHC results—TE buffer pH 9.0 is suggested, though citrate buffer pH 6.0 may serve as an alternative .

How do I optimize a Western blot protocol specifically for VCP detection?

For optimal VCP detection by Western blot:

• Sample preparation: Given VCP's molecular weight of 89 kDa, use 8-10% polyacrylamide gels for adequate resolution. Include protease inhibitors in lysis buffers to prevent degradation.

• Protein loading: Load 20-50 μg of total protein per lane for cell lysates, depending on VCP expression levels in your sample.

• Transfer conditions: For efficient transfer of high molecular weight VCP, use wet transfer systems with 10-20% methanol for 60-90 minutes at 100V, or overnight at 30V at 4°C.

• Blocking and antibody incubation: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature. Dilute primary VCP antibody to 1:1000 (or according to manufacturer specifications) and incubate overnight at 4°C for optimal binding.

• Detection: Use appropriate HRP-conjugated secondary antibodies (typically anti-mouse or anti-rabbit, depending on the primary antibody host) . Visualize using enhanced chemiluminescence with exposure times adjusted based on signal intensity.

To control for specificity, include a VCP knockout or knockdown sample when possible. Published research has demonstrated clear differences in VCP detection between wild-type and VCP knockout U2OS cells , providing a reliable control for antibody specificity.

How can VCP antibodies be used to study protein quality control and degradation pathways?

VCP plays a critical role in ER-associated degradation (ERAD) and the ubiquitin-proteasome system. To study these pathways using VCP antibodies:

• Degradation kinetics: Track substrate degradation by combining VCP antibodies with antibodies against ERAD substrates like αTCR. Research has shown that RNAi of VCP increases the half-life of αTCR approximately four-fold, despite showing only a modest 20-30% increase in steady-state levels due to diminished protein synthesis during ER stress .

• Accumulation of ubiquitinated proteins: Use VCP antibodies in combination with ubiquitin antibodies to demonstrate accumulation of polyubiquitinated proteins following VCP depletion. This approach has been documented to show significant increases in ubiquitinated proteins when VCP function is compromised .

• Co-immunoprecipitation studies: Employ VCP antibodies to pull down VCP and its associated complexes (like Ufd1-Npl4) to identify specific substrates and regulatory factors in degradation pathways.

• Stress pathway analysis: Combine VCP antibody staining with markers of ER stress (such as XBP1 splicing) to examine the relationship between VCP function and cellular stress responses .

For experimental design, include appropriate controls such as RNAi of VCP cofactors (Ufd1, Npl4) to distinguish between direct VCP effects and those mediated through specific complexes. Research has demonstrated that different outcomes can occur depending on whether VCP itself or its cofactors are depleted .

What controls should be included when using VCP antibodies in experimental validation?

When using VCP antibodies in experiments, the following controls are essential for proper validation:

• Positive controls: Include cell lines with confirmed VCP expression, such as RAW 264.7, HeLa, or SH-SY5Y cells, which have been documented to express detectable levels of VCP .

• Negative controls: Where possible, use VCP knockout cell lines as definitive negative controls. VCP KO U2OS cells have been successfully used to validate antibody specificity . Alternatively, VCP knockdown using validated siRNA or shRNA can serve as a functional negative control.

• Isotype controls: For flow cytometry and immunoprecipitation, include an appropriate isotype control (e.g., mouse IgG1 for monoclonal antibodies) to assess non-specific binding .

• Loading controls: In Western blot applications, always include housekeeping protein controls (β-actin, GAPDH) to normalize VCP levels across samples and ensure equal loading.

• Secondary antibody-only controls: Include samples without primary antibody to determine background signal from secondary antibody binding in immunostaining protocols.

• Peptide competition assays: When validating new lots or testing in new applications, consider using peptide competition with the immunogen peptide to confirm antibody specificity.

These controls are particularly important when investigating VCP in disease models or when using new tissue or cell types, where expression levels and patterns may differ from established models.

How can VCP antibodies be used to investigate its role in neurodegenerative diseases?

VCP mutations have been implicated in several neurodegenerative diseases including inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) and amyotrophic lateral sclerosis (ALS). VCP antibodies can be leveraged to investigate disease mechanisms through:

• Immunohistochemistry of patient tissues: Use VCP antibodies at 1:500-1:2000 dilution to examine VCP localization and aggregation patterns in affected tissues. Compare staining patterns between normal and disease tissues, focusing on inclusion bodies and areas of neurodegeneration.

• Co-localization studies: Combine VCP antibodies with markers for aggregated proteins (TDP-43, ubiquitin) using multi-color immunofluorescence to identify pathological protein interactions. This approach requires careful antibody selection to avoid host species cross-reactivity.

• Patient-derived models: Apply VCP antibodies to detect expression and localization changes in iPSC-derived neurons or glia from patients with VCP mutations compared to controls.

• Biochemical fractionation: Use VCP antibodies in Western blot analysis of soluble versus insoluble protein fractions to quantify shifts in VCP distribution in disease states, which may indicate pathological aggregation or altered function.

When designing these experiments, researchers should consider that VCP's role may vary across different neurodegenerative conditions, and antibody selection should be validated for each specific tissue type and preparation method.

How do I design experiments to study VCP translocation between cellular compartments?

VCP translocates from the ER to the nucleus following stimulation with growth factors like EGF . To effectively track this process:

• Subcellular fractionation with Western blotting:

  • Prepare nuclear, cytoplasmic, and membrane fractions using standard protocols

  • Run Western blots using VCP antibodies (1:1000 dilution)

  • Include compartment-specific markers (e.g., Lamin B for nucleus, GAPDH for cytoplasm, Calnexin for ER)

  • Quantify relative VCP distribution across fractions before and after stimulation

• Live-cell imaging with tagged VCP:

  • Create cells expressing fluorescently-tagged VCP

  • Validate expression pattern using VCP antibodies to ensure the tag doesn't disrupt localization

  • Perform time-lapse microscopy following stimulation

  • Quantify nuclear/cytoplasmic ratio over time

• Immunofluorescence with co-localization:

  • Fix cells at various time points after stimulation

  • Stain with VCP antibodies (1:400-1:1600 dilution) along with compartment markers

  • Use confocal microscopy to determine co-localization coefficients

  • Apply appropriate statistical analysis to quantify changes in distribution

• Stimulus response studies:

  • Compare different stimuli (EGF, stress conditions) for their effects on VCP translocation

  • Incorporate inhibitors of specific signaling pathways to identify translocation mechanisms

  • Include phospho-specific staining, as VCP phosphorylation has been linked to its cellular functions

For all these approaches, time course experiments are essential to capture the dynamics of translocation, with early time points (5-30 minutes) often revealing the most dramatic changes in VCP distribution following stimulation.

How can VCP antibodies be used to study the relationship between VCP and viral infections?

Recent research has revealed interesting connections between VCP and viral infections, particularly through viral citrullinated peptides (VCP) and Epstein-Barr virus (EBV). These connections can be investigated using VCP antibodies through:

• Detection of viral-induced citrullination: Use antibodies against viral citrullinated peptides to examine how viral infection alters protein citrullination. Research has shown that sera from early rheumatoid arthritis (ERA) patients react to deiminated proteins encoded by EBV, suggesting a potential viral etiology in this autoimmune disease .

• In-house ELISA development: Researchers can establish ELISAs for detecting both VCP (viral citrullinated peptide) antibodies and EBNA-1 (Epstein-Barr nuclear antigen-1) antibodies in patient sera. While such assays may show relatively low sensitivity, they demonstrate high specificity (>96%) .

• Comparative analysis: Compare VCP IgG and IgM antibody responses against the viral citrullinated peptide versus responses to EBNA-1 peptide. Studies have found significant differences in these responses, with VCP proving to be a better marker than EBNA-1 for distinguishing between patient groups .

• Temporal studies: Investigate the temporal relationship between viral infection markers and appearance of VCP antibodies to understand potential causative relationships in autoimmune disorders.

When designing these experiments, researchers should distinguish between the two uses of the VCP acronym: valosin-containing protein and viral citrullinated peptide. Both are relevant in different research contexts but represent distinct molecular entities.

What are the methodological considerations when using VCP antibodies in comparative studies across different species?

When conducting cross-species studies with VCP antibodies, researchers should consider:

• Epitope conservation: VCP is highly conserved across species, but subtle differences exist. Verify the epitope sequence recognized by your antibody and align it with the target species' VCP sequence. Many commercial VCP antibodies have validated reactivity with human and mouse VCP , with some also recognizing rat and monkey VCP .

• Validation strategy:

  • Perform Western blot analysis using tissue lysates from each species of interest

  • Include positive controls from validated species (e.g., human cell lines for human-reactive antibodies)

  • Consider using knockout or knockdown controls in at least one species to confirm specificity

  • When possible, test multiple VCP antibodies targeting different epitopes

• Application-specific considerations:

  • For IHC: Optimize antigen retrieval conditions separately for each species. While TE buffer pH 9.0 is recommended for human and mouse tissues, conditions may require adjustment for other species

  • For IF: Fixation conditions may need to be optimized for each species

  • For WB: Protein extraction methods may require species-specific modifications

• Quantitative comparisons: When comparing VCP levels across species, use relative quantification rather than absolute values. Ensure that loading controls are appropriate for cross-species comparisons (highly conserved housekeeping proteins).

• Technical replications: Increase technical replicates when working with less-validated species to ensure reliability of results.

By carefully addressing these considerations, researchers can confidently extend their VCP studies across species barriers while maintaining scientific rigor.

How do I troubleshoot weak or absent signals when using VCP antibodies in Western blots?

When encountering weak or absent VCP signals in Western blots, consider the following troubleshooting strategies:

• Sample preparation issues:

  • Ensure complete protein extraction with appropriate lysis buffers (RIPA or NP-40 based buffers with protease inhibitors)

  • Avoid excessive sample heating which may cause high molecular weight protein aggregation

  • For membrane-associated VCP populations, consider using stronger detergents or membrane fraction enrichment

• Technical parameters:

  • Increase antibody concentration gradually (start with 1:500 instead of 1:1000)

  • Extend primary antibody incubation time to overnight at 4°C

  • Optimize transfer conditions for high molecular weight proteins (89 kDa) by decreasing methanol concentration and extending transfer time

  • Consider using PVDF membranes instead of nitrocellulose for better protein retention

• Detection optimization:

  • Use enhanced chemiluminescence (ECL) substrates designed for high sensitivity

  • Extend exposure times gradually

  • Consider using fluorescent secondary antibodies for more stable signals and quantitative analysis

• VCP-specific considerations:

  • VCP may undergo post-translational modifications or form complexes that affect epitope accessibility; try reducing agent concentration adjustments

  • If studying stress conditions, verify VCP expression levels, as translocation between compartments may occur

  • Check if your experimental conditions might be affecting VCP stability or expression

• Antibody validation:

  • Test a different VCP antibody targeting an alternative epitope

  • Verify antibody functionality with a positive control sample (HeLa or SH-SY5Y cell lysates)

If signals remain problematic after these adjustments, consider whether your experimental conditions might be fundamentally altering VCP expression or structure, which could itself be an interesting research finding.

How should I interpret discrepancies between VCP antibody results in different applications?

When faced with discrepancies in VCP antibody results across different applications (e.g., positive in Western blot but negative in IHC), consider these interpretation guidelines:

• Application-specific epitope accessibility:

  • In fixed tissues or cells (IHC/IF), epitopes may be masked due to fixation-induced cross-linking or conformational changes

  • In denatured samples (WB), linear epitopes are exposed that might be hidden in folded proteins

  • Solution: Try multiple VCP antibodies targeting different epitopes, or modify fixation/retrieval protocols

• Expression level thresholds:

  • Western blot can detect lower expression levels through sample concentration

  • IHC/IF have higher detection thresholds dependent on signal amplification methods

  • Flow cytometry may require higher expression levels for reliable detection

  • Solution: Adjust antibody concentration or detection method sensitivity for each application

• Post-translational modifications:

  • VCP undergoes phosphorylation after T-cell activation , which may affect epitope recognition

  • Ubiquitination or other modifications may occur under stress conditions

  • Solution: Use modification-specific antibodies or treatments that remove specific modifications

• Experimental conditions impact:

  • Research has shown that VCP can translocate between cellular compartments upon stimulation

  • Stress conditions may alter VCP levels or localization

  • Solution: Standardize experimental conditions and include appropriate time-course analyses

• Scientific interpretation framework:

  • Consider all results as potentially valid but revealing different aspects of VCP biology

  • Document conditions precisely to enable reproduction

  • Report discrepancies transparently as they may reveal novel biology

A concrete example comes from studies showing that while RNAi of VCP causes only a modest 20-30% increase in αTCR levels (as measured by steady-state analysis), half-life measurements reveal a four-fold increase in stability . This apparent discrepancy was explained by understanding that diminished protein synthesis during ER stress counteracted the effects of diminished ERAD.

How are VCP antibodies being used to investigate novel functions beyond protein degradation?

Recent research is expanding our understanding of VCP functions beyond its classical roles in protein degradation:

• DNA damage repair pathways: VCP antibodies are being used to study the interaction between VCP and BRCA1 . Researchers can employ co-immunoprecipitation with VCP antibodies followed by Western blotting for BRCA1 to elucidate how VCP contributes to DNA damage repair mechanisms.

• Nuclear functions: Following the observation that EGF stimulation leads to VCP translocation to the nucleus , researchers are using subcellular fractionation combined with VCP immunoblotting to track nuclear VCP during various cellular processes. This approach is revealing potential roles in transcriptional regulation and nuclear protein quality control.

• T-cell signaling: VCP phosphorylation occurs after T-cell activation, and this modification appears to regulate cell growth . Phospho-specific antibodies used alongside standard VCP antibodies can help map the signaling cascades involved in this regulation.

• Viral pathogenesis: The connection between viral infection, citrullinated peptides, and autoimmunity is being explored using antibodies against both cellular VCP and viral citrullinated peptides . This research may reveal novel mechanisms of virus-induced autoimmune disorders.

For researchers investigating these emerging areas, combining VCP antibodies with domain-specific mutants and advanced imaging techniques like super-resolution microscopy will be particularly valuable in distinguishing between VCP's multiple cellular functions.

What are the current limitations of VCP antibodies and how might they be addressed in future research?

Current VCP antibody limitations and potential future solutions include:

• Conformational specificity:

  • Current limitation: Most available antibodies cannot distinguish between different conformational states of VCP (ATP-bound, ADP-bound, or transitional states)

  • Future direction: Development of conformation-specific antibodies could enable tracking of VCP's functional cycle and identify dysregulation in disease states

• Complex-specific recognition:

  • Current limitation: Antibodies generally recognize VCP regardless of its binding partners (Ufd1-Npl4, p47)

  • Future direction: Designing antibodies that selectively recognize specific VCP complexes would help distinguish between different functional pools of VCP

• Post-translational modification detection:

  • Current limitation: Few antibodies specifically recognize modified forms of VCP (phosphorylated, ubiquitinated)

  • Future direction: Development of a panel of modification-specific antibodies would enable more detailed mapping of VCP regulation

• Live-cell applications:

  • Current limitation: Current antibodies are primarily useful in fixed samples or biochemical applications

  • Future direction: Development of intrabodies or nanobodies against VCP that function in living cells could revolutionize dynamic studies of VCP function

• Cross-reactivity challenges:

  • Current limitation: Some antibodies may cross-react with other AAA-family ATPases

  • Future direction: Improved epitope mapping and validation against knockout controls for multiple AAA ATPases could enhance specificity

• Sensitivity variability:

  • Current limitation: In-house ELISA methods for viral citrullinated peptide antibodies show high specificity but low sensitivity

  • Future direction: Optimization of detection methods, alternative epitopes, or signal amplification techniques could improve sensitivity while maintaining specificity

These improvements would significantly enhance the utility of VCP antibodies for understanding both normal cellular functions and disease-related mechanisms involving this multifunctional protein.